Pharmacotherapy for treatment-resistant schizophrenia

QR Code

Pharmacotherapy for treatment-resistant schizophrenia

Meghan E Mcilwain1,2, Jeff Harrison1, Amanda J Wheeler1,3, Bruce R Russell1,21School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; 2Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand;...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Meghan E Mcilwain, Jeff Harrison, Amanda J Wheeler, et al
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2011
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/36b5e466ed7f4db5b9ccd890eec48990
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Role of aripiprazole in treatment-resistant schizophrenia
par: Mossaheb N, et autres
Publié: (2012)

Pharmacotherapy of panic disorder
par: Charles B Pull, et autres
Publié: (2008)

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
par: Xinhua&nbsp;S Ren, et autres
Publié: (2009)

Suicide risk in depression and bipolar disorder: Do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent?
par: Maurizio Pompili, et autres
Publié: (2008)

Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia
par: Hongyan Zhang, et autres
Publié: (2011)

Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia
par: Terzić T, et autres
Publié: (2015)

Profile of blonanserin for the treatment of schizophrenia
par: Tenjin T, et autres
Publié: (2013)

Role of sublingual asenapine in treatment of schizophrenia
par: Citrome L
Publié: (2011)

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
par: Srihari Gopal, et autres
Publié: (2011)

Profile of minocycline and its potential in the treatment of schizophrenia
par: Zhang L, et autres
Publié: (2014)

Towards a framework for treatment effectiveness in schizophrenia
par: Juckel G, et autres
Publié: (2014)

Atypical antipsychotics in the treatment of early-onset schizophrenia
par: Hrdlicka M, et autres
Publié: (2015)

Augmentation with antidepressants in schizophrenia treatment: benefit or risk
par: Mao YM, et autres
Publié: (2015)

Once-monthly paliperidone injection for the treatment of schizophrenia
par: Delia Bishara
Publié: (2010)

Yokukansan and its ingredients as possible treatment options for schizophrenia
par: Yu CH, et autres
Publié: (2014)

Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension
par: Amresh Shrivastava, et autres
Publié: (2010)

Psychosurgery for schizophrenia: history and perspectives
par: Soares MS, et autres
Publié: (2013)

Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment
par: Iasevoli F, et autres
Publié: (2013)

Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia
par: Jeffrey R Bishop, et autres
Publié: (2008)

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments
par: Chien WT, et autres
Publié: (2013)

An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia
par: Hirano J, et autres
Publié: (2013)

Recurrent schizophrenia-like psychosis as first manifestation of epilepsy: a diagnostic challenge in neuropsychiatry
par: Willem MA Verhoeven, et autres
Publié: (2010)

Soccer practice as an add-on treatment in the management of individuals with a diagnosis of schizophrenia
par: Battaglia G, et autres
Publié: (2013)

The utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment
par: Tompsett T, et autres
Publié: (2018)

Quality of life of patients with schizophrenia treated in foster home care and in outpatient treatment
par: Mihanović M, et autres
Publié: (2015)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
par: Rosaria Di Lorenzo, et autres
Publié: (2010)

Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
par: Mario Louz&atilde;, et autres
Publié: (2010)

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar&nbsp;I disorder
par: Delia Bishara, et autres
Publié: (2009)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
par: Ascher-Svanum H, et autres
Publié: (2012)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
par: Zhao Y, et autres
Publié: (2013)

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
par: Chen L, et autres
Publié: (2013)

The cost of schizophrenia in Japan
par: Sado M, et autres
Publié: (2013)

Jumping to conclusions in schizophrenia
par: Evans SL, et autres
Publié: (2015)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
par: Azekawa T, et autres
Publié: (2011)

Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor? A case series of 39 patients
par: Yoshimura B, et autres
Publié: (2013)

Comparing the influences of age and disease on the Brief Assessment of Cognition in Schizophrenia in Japanese patients with schizophrenia
par: Kaneda A, et autres
Publié: (2013)

Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study
par: Zhu W, et autres
Publié: (2014)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
par: Ascher-Svanum H, et autres
Publié: (2014)

Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
par: Ann E Maloney, et autres
Publié: (2010)

Erratum:&nbsp;An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967&ndash;976
par: Colombo GL, et autres
Publié: (2009)